J Neurochem 2005
Incorrect storage can compromise sterility, shorten usability, or risk contamination
Does GLP-1 Help With Rheumatoid Arthritis
Per HumeCare's Medications Safety Information, these medications should not be used during pregnancy, based on potential risks identified in animal studies, and there is no established weight-loss benefit that would justify use during pregnancy
Starting the MindBody System 23 weeks before beginning your taper may help ease the transition by kickstarting natural GLP-1 Activation and microbiome changes.* However you transition, remember this is a journey, not a quick fix
Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly
